Growth-differentiation factor-15: a novel biomarker in patients with diastolic dysfunction?

Growth differentiation factor-15 (GDF-15), a stress-responsive transforming growth factor-s-related cytokine, is elevated and independently related to an adverse prognosis in systolic heart failure. Objective: This study aimed to investigate plasma levels of GDF-15 in patients with preclinical diastolic dysfunction or heart failure with normal ejection fraction (HFnEF). Methods: We evaluated 119 patients with normal ejection fraction referred for an elective coronary angiography, 75 (63%) of whom had coronary artery disease. Subjects were classified as having either mild left ventricular diastolic dysfunction (LVDD grade I, n = 61), HFnEF (LVDD grade II or III, n = 38) or normal diastolic function (controls, n = 20). In a subgroup of 20 subjects, changes in cardiac output (CO) were measured by inert gas rebreathing (InnocorTM) in response to an orthostatic hemodynamic test. Results: Growth differentiation factor-15 levels in HFnEF (median 1.08, interquartile range (0.88-1.30) ng/ml) were significantly higher than in controls (0.60 (0.50-0.71) ng/ml, p = 0.003) and in patients with LVDD grade I (0.78 (0.62- 1.04) ng/ml, p < 0.001). In addition, GDF-15 was significantly elevated in patients with LVDD grade I compared to controls (p = 0.003). Furthermore, GDF-15 was correlated with echocardiographic markers of diastolic dysfunction and was correlated with the magnitude of CO response to the change in body position from standing to supine (r = -0.67, p = 0.005). Conclusion: Growth differentiation factor-15 levels are elevated in subjects with HFnEF and can differentiate normal diastolic function from asymptomatic LVDD. In addition, GDF-15 is associated with a reduced cardiac output response in the orthostatic hemodynamic test. (Arq Bras Cardiol. 2011; (online).ahead print, PP.0-0)